MAPK Signaling and Angiopoietin-2 Contribute to Endothelial Permeability in Capillary Malformations., PMID:40235979
RBMS3-loss impedes TRIM21-induced ubiquitination of ANGPT2 in an RNA-independent manner and drives sorafenib resistance in hepatocellular carcinoma., PMID:40069332
Systemic counterregulatory response of angiopoietin-2 after intravitreal injections with faricimab for nAMD., PMID:39920326
Emerging clinical evidence of a dual role for Ang-2 and VEGF-A blockade with faricimab in retinal diseases., PMID:39708087
Inhibition of Angiopoietin-2 rescues sporadic brain arteriovenous malformations by reducing pericyte loss., PMID:39636449
Ocular Pharmacodynamics of Intravitreal Faricimab in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema., PMID:39535745
Angiopoietin-2 reverses endothelial cell dysfunction in progeria vasculature., PMID:39422121
Optimization of individualized faricimab dosing for patients with diabetic macular edema: Protocol for the SWAN open-label, single-arm clinical trial., PMID:39388397
A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer., PMID:39348472
VEPTP inhibition with an extracellular domain targeting antibody did not restore albuminuria in a mouse model of diabetic kidney disease., PMID:39324545
Contribution of plasma levels of VEGF-A and angiopoietin-2 in addition to a genetic variant in KCNAB1 to predict the risk of bevacizumab-induced hypertension., PMID:38992025
Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma., PMID:38934093
Preventive effects of vasohibin-2-targeting peptide vaccine for diabetic nephropathy., PMID:38695075
Status of alternative angiogenic pathways in glioblastoma resected under and after bevacizumab treatment., PMID:38619734
TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2., PMID:38382813
Targeting VEGF using Bevacizumab attenuates sepsis-induced liver injury in a mouse model of cecal ligation and puncture., PMID:38313162
Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials., PMID:38158159
An agonistic anti-Tie2 antibody suppresses the normal-to-tumor vascular transition in the glioblastoma invasion zone., PMID:36828931
Assessment of Angiopoietin-2 Single Nucleotide Polymorphism in Patients with Rheumatoid Arthritis., PMID:36562898
MYBL1 induces transcriptional activation of ANGPT2 to promote tumor angiogenesis and confer sorafenib resistance in human hepatocellular carcinoma., PMID:35987690
Akt1-dependent expression of angiopoietin 1 and 2 in vascular smooth muscle cells leads to vascular stabilization., PMID:35931736
Effect of Novel Biotherapeutic Elevating Angiopoietin 1 on Progression of Diabetic Nephropathy in Diabetic/Obese Mice., PMID:35779860
Viewpoints: Dual-blocking antibody against VEGF-A and angiopoietin-2 for treating vascular diseases of the eye., PMID:35396185
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials., PMID:35085503
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials., PMID:35085502
Structural insights into the clustering and activation of Tie2 receptor mediated by Tie2 agonistic antibody., PMID:34725372
COL10A1 is a novel factor in the development of choroidal neovascularization., PMID:34520774
Activated mesangial cells induce glomerular endothelial cells proliferation in rat anti-Thy-1 nephritis through VEGFA/VEGFR2 and Angpt2/Tie2 pathway., PMID:33987885
Concentrated Secretome of Adipose Stromal Cells Limits Influenza A Virus-Induced Lung Injury in Mice., PMID:33804896
Association of circulating protein biomarkers with clinical outcomes of durvalumab in head and neck squamous cell carcinoma., PMID:33796405
Endothelial cells response to neutrophil-derived extracellular vesicles miRNAs in anti-PR3 positive vasculitis., PMID:33527387
Angiopoietin-2 Promotes Inflammatory Activation in Monocytes of Systemic Sclerosis Patients., PMID:33333969
Combining 1,4-dihydroxy quininib with Bevacizumab/FOLFOX alters angiogenic and inflammatory secretions in ex vivo colorectal tumors., PMID:33008336
Targeting Angiopoietin in Retinal Vascular Diseases: A Literature Review and Summary of Clinical Trials Involving Faricimab., PMID:32785136
Antiangiogenic immunotherapy suppresses desmoplastic and chemoresistant intestinal tumors in mice., PMID:32015230
Bevacizumab treatment of meningeal melanoma metastases., PMID:31915016
Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy., PMID:31889004
New therapeutic targets in the treatment of age-related macular degeneration., PMID:31787390
Dual Pharmacological Inhibition of Angiopoietin-2 and VEGF-A in Murine Experimental Sepsis., PMID:31726451
Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF., PMID:31597643
High levels of Notch intracellular cleaved domain are associated with stemness and reduced bevacizumab efficacy in patients with advanced colon cancer., PMID:31578584
Rapid Development of Glaucoma Via ITV Nonselective ANGPT 1/2 Antibody: A Potential Role for ANGPT/TIE2 Signaling in Primate Aqueous Humor Outflow., PMID:31574535
Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease., PMID:31513439
Efficacy of a Bispecific Antibody Co-Targeting VEGFA and Ang-2 in Combination with Chemotherapy in a Chemoresistant Colorectal Carcinoma Xenograft Model., PMID:31394786
High baseline Tie1 level predicts poor survival in metastatic breast cancer., PMID:31340773
Bone marrow pericyte dysfunction in individuals with type 2 diabetes., PMID:31001672
Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial., PMID:30905643
Angiopoietin-2 Inhibition Rescues Arteriovenous Malformation in a Smad4 Hereditary Hemorrhagic Telangiectasia Mouse Model., PMID:30744395
Oligodendrocytes Up-regulate the Invasive Activity of Glioblastoma Cells via the Angiopoietin-2 Signaling Pathway., PMID:30711932
Angiopoietin-2 exacerbates cardiac hypoxia and inflammation after myocardial infarction., PMID:30295643
For research use only. Not for human or drug use.
